Number of individual grade ≥3 toxicities (day −7 to day +100 post-AHCT)
| . | Total . | Age 60-69 y . | Age ≥70 y . |
|---|---|---|---|
| Sample size | 346 (100) | 279 (80.6) | 67 (19.4) |
| Number of individual grade ≥ 3 toxicities day −7 to day +100 post-HCT | 874 (100) | 624 (100) | 250 (100) |
| Febrile neutropenia (no source) | 220 (25) | 172 (28) | 48 (19) |
| Infection | 157 (18) | 123 (20) | 34 (14) |
| Oral/GI | 193 (22) | 147 (24) | 46 (18) |
| Cardiovascular | 136 (16) | 78 (12) | 58 (23) |
| Pulmonary | 44 (5.0) | 32 (5.1) | 12 (4.8) |
| Metabolic | 37 (4.2) | 24 (3.8) | 13 (5.2) |
| Skin | 24 (2.7) | 15 (2.4) | 9 (3.6) |
| Neurologic | 18 (2.1) | 11 (1.8) | 7 (2.8) |
| Renal | 11 (1.3) | 8 (1.3) | 3 (1.2) |
| Hematologic | 12 (1.4) | 5 (0.8) | 7 (2.8) |
| Hepatic | 5 (0.6) | 4 (0.6) | 1 (0.4) |
| Immune | 3 (0.3) | 1 (0.2) | 2 (0.8) |
| Musculoskeletal and connective tissue | 5 (0.6) | 3 (0.5) | 2 (0.8) |
| Other | 9 (0.9) | 1 (0.2) | 8 (3.2) |
| . | Total . | Age 60-69 y . | Age ≥70 y . |
|---|---|---|---|
| Sample size | 346 (100) | 279 (80.6) | 67 (19.4) |
| Number of individual grade ≥ 3 toxicities day −7 to day +100 post-HCT | 874 (100) | 624 (100) | 250 (100) |
| Febrile neutropenia (no source) | 220 (25) | 172 (28) | 48 (19) |
| Infection | 157 (18) | 123 (20) | 34 (14) |
| Oral/GI | 193 (22) | 147 (24) | 46 (18) |
| Cardiovascular | 136 (16) | 78 (12) | 58 (23) |
| Pulmonary | 44 (5.0) | 32 (5.1) | 12 (4.8) |
| Metabolic | 37 (4.2) | 24 (3.8) | 13 (5.2) |
| Skin | 24 (2.7) | 15 (2.4) | 9 (3.6) |
| Neurologic | 18 (2.1) | 11 (1.8) | 7 (2.8) |
| Renal | 11 (1.3) | 8 (1.3) | 3 (1.2) |
| Hematologic | 12 (1.4) | 5 (0.8) | 7 (2.8) |
| Hepatic | 5 (0.6) | 4 (0.6) | 1 (0.4) |
| Immune | 3 (0.3) | 1 (0.2) | 2 (0.8) |
| Musculoskeletal and connective tissue | 5 (0.6) | 3 (0.5) | 2 (0.8) |
| Other | 9 (0.9) | 1 (0.2) | 8 (3.2) |
All data are n (%).